Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etripamil Nasal Spray for Paroxysmal Supraventricular Tachycardia in Chinese Patients
NCT05410860Phase 3Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in paroxysmal supraventricular tachycardia (PSVT) comparing Etripamil NS 70 mg with Placebo (2 arms). Primary endpoint: Time to an adjudicated termination of a positively adjudicated episode of PSVT and conversion to sinus rhythm (SR) at 30 months. Started Jun 2022; status: completed.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NCT05410860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410860.